You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Virtual Bone Biopsy: Transfer to the clinical arena

    SBC: MICROMRI, INC.            Topic: N/A

    Osteoporosis is a major community health problem for which several effective FDA approved therapies exist, but which remains largely undiagnosed and untreated. While bone densitometry using dual-energy x-ray absorptiometry (DXA) is the current "gold standard" in osteoporosis diagnosis, controlled clinical trials have highlighted its sensitivity and specificity limitations at the individual patient ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Low Antigenicity Factor VIII

    SBC: Octagen Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Octagen's broad, long-term objective is to complete the clinical development and secure FDA approval of its b-domain deleted recombinant factor VIII (OBI-1), a low antigenicity version of factor VIM (fVIII). OBI-1 is designed for the treatment of patients with inhibitory, neutralizing antibodies to human fVIII. Such "inhibitor" patients include congenital hemop ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  3. Lactoferrin as an Adjuvant for Cellular Immunity

    SBC: Pharmareview Corporation            Topic: N/A

    The Specific Aims of the proposal will be modified to reflect a change in scope, according to recommendations from the review panel. Specifically, the revised scope of the project will now only include AIM I and AIM II of the proposal. There will be no change in scope to the first two aims. All experiments proposed in AIMs I and II can be accelerated to meet the two year time commitment. Regarding ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  4. Instant Kit Synthesis of 62Cu Radiopharmaceuticals

    SBC: PROPORTIONAL TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Positron Emission Tomography (PET) is a rapidly emerging non-invasive imaging technique with the exceptional ability to provide quantitative functional information. Unfortunately, this modality is currently limited to a single approved radiopharmaceutical agent, 18F-FDG, which measures tumor metabolism. The potential of PET in oncology can be advanced substa ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  5. Interactive Image Guided Closed Loop Thermal Therapy

    SBC: Biotex, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this Phase II Competing Continuation research project is to complete the Phase I clinical trial of a new magnetic resonance imaging guided minimally invasive treatment for focal brain tumors. Over the past four years, BioTex has developed the Visualase(r) thermal therapy system for treatment of localized cancers by using temperature-sensitive mag ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Cross-enterprise access to cancer imaging data

    SBC: Hx Technologies, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): We propose to launch the first commercial service enabling physicians at unaffiliated hospitals to directly retrieve their patients' digital images and reports from each other on-demand. Despite significant societal need and market demand, US hospitals remain islands of mutually inaccessible data even as patients move between them. Even the most vulnerable p ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a transgenic rat to study brain aging

    SBC: INFLAME THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Neuro-inflammation is thought to be an important factor in age-dependent loss of neuron associated with Alzheimer's disease. We seek STTR funding to develop a unique transgenic rat that serves as a model for chronic neuro-inflammation and age-dependent loss of neurons. Presently, no other animal model offers specific patterns of neuro-inflammation, presence of ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a transgenic rat to study brain aging

    SBC: INFLAME THERAPEUTICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Neuro-inflammation is thought to be an important factor in age-dependent loss of neuron associated with Alzheimer's disease. We seek STTR funding to develop a unique transgenic rat that serves as a model for chronic neuro-inflammation and age-dependent loss of neurons. Presently, no other animal model offers specific patterns of neuro-inflammation, presence of ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic for the Negative Symptoms of Schizophrenia

    SBC: Darpharma, Inc.            Topic: N/A

    DESCRIPTION (PROVIDED BY APPLICANT): Schizophrenia affects roughly 1% of the world's population, with more than two million Americans afflicted in any given year, and an estimated 30-50 million people worldwide. Treatment with available antipsychotic medications often effectively attenuates the positive symptoms of schizophrenia without improvement in the negative symptoms or cognitive deficits. F ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Synthesis and Evaluation of a Novel Anti-HIV Agent

    SBC: Kucera Pharmaceutical Company            Topic: N/A

    The long-term goal of this research is to develop a drug that is safe and effective against drug-resistant human immunodeficiency virus (HIV) infection. Several challenges confront current anti-HIV chemotherapy. The frequency of drug-resistant and multidrug-resistant HIV-1 is increasing. Toxicities associated with current HIV medications often result in the discontinuation of these therapies. Phys ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government